A phase 3, double-blind efficacy, safety and dose-response study of lofexidine (S
Ended Cooperative Agreement Awarded Last action
- Award ID
- U01DA033276
- Recipient
-
MDD US Operations, LLC UEI NKGSYBV5UGN1
- Awarding agency
-
National Institutes of Health
Department of Health and Human Services
- Obligated
- $18,307,936
Award facts
- Assistance listing
- 93.279 Drug Use and Addiction Research Programs
- Completion date
- Originally
- Funding agency
- Department of Health and Human Services
- Place of performance
- Brownsboro Village, KY 40207, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $813,971 | |
| Amendment | $5,967,600 | |
| Amendment | -$184,531 | |
| Amendment | $5,728,896 | |
| Original award | $5,982,000 |
Quick answers
Who received award U01DA033276?
U01DA033276 was awarded to MDD US Operations, LLC by National Institutes of Health (Department of Health and Human Services) on September 30, 2012.
How much is award U01DA033276 worth?
$18,307,936 has been obligated on U01DA033276.
Which agency awarded U01DA033276?
National Institutes of Health (Department of Health and Human Services) awarded U01DA033276, with funding from Department of Health and Human Services.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award